Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut

Smilow Cancer Hospital Phase 1 Unit is a clinical research site located in New Haven, Connecticut, United States 06511.

Crixeo Health Trust Score: 75/100 (FAIR). This profile has not yet been claimed by the site owner.

Smilow Cancer Hospital Phase 1 Unit has participated in 12 clinical trials with 7 currently active.

Therapeutic areas: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma.

Sponsors: Pfizer, Prelude Therapeutics, Gilead Sciences.

Sponsor Feasibility Report

Trust Score: 75/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Smilow Cancer Hospital Phase 1 Unit?

Smilow Cancer Hospital Phase 1 Unit has a Crixeo Trust Score of 75/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Smilow Cancer Hospital Phase 1 Unit conducted?

Smilow Cancer Hospital Phase 1 Unit has 12 clinical trials on record, with 7 currently active. Their work covers Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma.

Is Smilow Cancer Hospital Phase 1 Unit accredited by Crixeo Health?

Yes — Smilow Cancer Hospital Phase 1 Unit holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Smilow Cancer Hospital Phase 1 Unit?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.